Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Geldanamycin analogs.

E A Sausville1

  • 1Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, USA. esausville@umm.edu

Journal of Chemotherapy (Florence, Italy)
|February 4, 2005
PubMed
Summary
This summary is machine-generated.

Benzoquinoid ansamycins, like 17AAG, target heat shock protein 90 (Hsp90) clients. The analog 17DMA shows promise for improved pharmaceutical applications over 17AAG.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Bone marrow transplantation·2016
Same author

Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes.

Cell death and differentiation·2005
Same author

Target selection issues in drug discovery and development.

Journal of chemotherapy (Florence, Italy)·2005
Same author

The hollow fibre model in cancer drug screening: the NCI experience.

European journal of cancer (Oxford, England : 1990)·2004
Same author

A potential role for imaging technology in anticancer efficacy evaluations.

European journal of cancer (Oxford, England : 1990)·2004
Same author

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.

The Journal of urology·2004
Same journal

Eravacycline in sepsis complicated by <i>Clostridioides difficile</i> infection: a brief case series.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol for <i>Stenotrophomonas maltophilia</i> infections: real-world evidence from a multicenter study and a comprehensive literature review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol susceptibility in carbapenem-resistant <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Stenotrophomonas maltophilia</i> isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome.

Journal of chemotherapy (Florence, Italy)·2026
See all related articles

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Benzoquinoid ansamycins are a class of compounds known to modulate heat shock protein 90 (Hsp90) client proteins.
  • Hsp90 chaperones critical proteins, including tyrosine kinases, steroid receptors, and cell cycle kinases, influencing cellular processes.

Purpose of the Study:

  • To compare the therapeutic potential of 17allylaminol7demethoxygeldanamycin (17AAG) and its analog 17dimethyl-aminoethylaminogeldanamycin (17DMA).
  • To evaluate 17DMA for potential preferential pharmaceutical features compared to the clinically used 17AAG.

Main Methods:

  • The study focuses on the molecular mechanisms of benzoquinoid ansamycins.
  • Comparative analysis of 17AAG and 17DMA based on their interaction with Hsp90 client proteins.

Related Experiment Videos

Main Results:

  • Benzoquinoid ansamycins effectively downregulate Hsp90-chaperoned molecules.
  • 17AAG has advanced to clinical use.
  • 17DMA exhibits characteristics suggesting advantageous pharmaceutical properties.

Conclusions:

  • 17DMA represents a potentially improved analog of 17AAG for therapeutic applications.
  • Targeting Hsp90 clients with benzoquinoid ansamycins remains a promising strategy in drug development.